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Aims. Acetylsalicylic acid (ASA) is widely used for the prevention of atherothrombotic events in patients with chronic coronary
artery disease (CAD) and peripheral artery disease (PAD), but the risk of vascular events remains high. We aimed at identifying
randomised controlled trials (RCTs) on antithrombotic treatments in patients with chronic CAD or PAD. Methods. Searches
were conducted on MEDLINE, EMBASE, and CENTRAL on March 1st, 2018. This systematic review (SR) uses a narrative
synthesis to summarize the evidence for the efficacy and safety of antiplatelet and anticoagulant therapies in the population of
both chronic CAD or PAD patients. Results. Four RCTs from 27 publications were included. Study groups included 15,603 to
27,395 patients. ASA alone was the most extensively studied (n = 3); other studies included rivaroxaban with or without ASA
(n = 1), vorapaxar alone (n = 1), and clopidogrel with (n = 1) or without ASA (n = 1). Clopidogrel alone and clopidogrel plus
ASA compared to ASA presented similar efficacy with comparable safety profile. Rivaroxaban plus ASA significantly reduced
the risk of the composite of cardiovascular death, myocardial infarction, and stroke compared to ASA alone, although major
bleeding with rivaroxaban plus ASA increased. Conclusion. There is limited and heterogeneous evidence on the prevention of
atherothrombotic events in patients with chronic CAD or PAD. Clopidogrel alone and clopidogrel plus ASA did not
demonstrate superiority over ASA alone. A combination of rivaroxaban plus ASA may offer significant additional benefit in
reducing cardiovascular outcomes, yet it may increase the risk of bleeding, compared to ASA alone.
1. Introduction
Atherosclerosis is one of the most common causes of mortal-
ity and morbidity worldwide. It can affect any artery in the
body including arteries in the heart, brain, arms, legs, pelvis,
and kidneys. Atherosclerosis may cause CAD when there is a
restriction of blood flow to the heart, or PAD, which causes
stenosis and occlusion of noncerebral and noncoronary
arteries affecting the arteries of the lower extremities and
sometimes the carotid arteries [1, 2]. CAD or PAD poses a
substantial clinical and economic burden, being associated
with a high risk of cardiovascular (CV) death, MI, and stroke,
which increases further in patients with prior MI, stroke, or
renal impairment.
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Acetylsalicylic acid (ASA) alone represents the standard
of care for the prevention of atherothrombotic events in
patients with chronic CAD or PAD. Despite the wide use of
ASA, which is effective in the prevention of atherothrombotic
events in patients with chronic CAD or PAD, the risk of vas-
cular events remains high [3–6].
Rivaroxaban is an oral factor Xa inhibitor anticoagulant
which has been approved for various indications [7–14].
Recently, the COMPASS study conducted with the aim to
investigate the efficacy of rivaroxaban in preventing recur-
rent cardiovascular events in the population of both chronic
CAD or PAD patients showed that rivaroxaban 2.5mg twice
a day (bid) plus ASA effectively prevents atherothrombotic
events [15]. Rivaroxaban 2.5mg, coadministered with ASA,
is indicated for the prevention of atherothrombotic events
in adult patients with coronary artery disease (CAD) or
symptomatic peripheral artery disease (PAD) at high risk of
ischaemic events [16].
2. Aim
The aim of this systematic review (SR) was to identify and
summarise the current evidence on therapeutic approaches
in the prevention of atherothrombotic events in the popula-
tion of both chronic CAD or PAD patients focusing on ran-
domised controlled trials (RCTs).
3. Methods
We conducted an SR of RCTs assessing the efficacy and safety
of the anticoagulants and antiplatelet therapies in the preven-
tion of atherothrombotic events in the population of both
chronic CAD or PAD patients. The PRISMA guidelines were
followed [17]. The protocol of the SR was not preregistered in
PROSPERO.
Detailed inclusion and exclusion criteria are provided in
Table 1. To ensure the similar quality of evidence found
and because of the specifics of the population, observational
studies were excluded. The searches were conducted via the
OVID interface on March 1, 2018, in MEDLINE® (1946 to
present) and EMBASE® (1974 to present) and via Wiley
Library in the Cochrane Central Register of Controlled Trials
(CENTRAL). Reference lists of relevant studies were manu-
ally searched for additional articles. No restrictions in terms
of language, timeframe, or geographical scope were applied.
Conference abstracts published before 2015 were excluded,
as the results of these studies are likely to have been already
released as manuscripts.
The search and selection of studies were performed by
two reviewers; when necessary, a third reviewer resolved
any discrepancies (VT, KBO, and AJ). The search strate-
gies are detailed in Tables S1 and S2. Extracted data
included publication characteristics, study details, patient
characteristics, results, and study limitations. A reviewer
extracted data from selected publications and the quality
of the extraction was evaluated by a second reviewer
(VT, KBO, and AJ). The clinicaltrial.gov was searched to
supplement the data found in the publications. The risk of
bias of the included studies was assessed using the RoB 2.0
tool [18].
Due to the high level of heterogeneity of the included
population and interventions, statistical meta-analysis was
not conducted.
4. Results
A total of 21,805 articles were identified: 21,759 from the elec-
tronic databases including MEDLINE, EMBASE, and CEN-
TRAL and 46 from additional sources that were publications
obtained through reference screening of relevant studies
(Figure 1). A total of 27 publications reporting the results of
4 studies (Table 2) were included in the narrative synthesis.
4.1. Study and Patient Characteristics. Detailed study charac-
teristics are provided in Table 2. All of the included studies
were international and sponsored by pharmaceutical compa-
nies. The trial phase was reported for 3 studies; all 3 studies
were reported as phase III trials. Studies randomised from
15,603 to 27,395 patients. The largest study identified was
the COMPASS study [15]. The proportion of men was
between 70% and 80%. Three studies reported the mean
age of the population examined. Of these, 1 study included
patients aged below 65 years on average [19], while 2 other
studies included patients between 65 and 74 years [1, 15].
The mean follow-up in all studies exceeded 12 months.
Vorapaxar vs. placebo [20] was investigated at the most
extended follow-up (the median of 30 months of follow-
up), followed by the study of clopidogrel plus ASA vs. ASA
alone [1], rivaroxaban with and without ASA vs. ASA alone
[15], and clopidogrel alone vs. ASA alone [19].
As it is the current standard of care, ASA alone was the
most examined treatment across the identified studies
(n = 3). Rivaroxaban (alone and plus ASA), vorapaxar alone,
and clopidogrel (alone and plus ASA) were investigated in
single studies. The highest dose of ASA (325mg once daily
(od)) was examined in the CAPRIE study [19]. The COM-
PASS [15] and CHARISMA [1] studies investigated doses
of ASA at 100mg od and 75-162mg od, respectively.
Inclusion criteria in identified studies varied significantly.
The COMPASS [15] study included patients with chronic
atherosclerotic vascular disease, while patients with recent
nonlacunar ischaemic stroke were excluded. The CHARISMA
[1] study randomised a broader population, including chronic
patients with either documented CAD, symptomatic PAD,
cerebrovascular disease, or multiple atherothrombotic risk
factors. The CAPRIE [19] trial recruited a population includ-
ing both chronic and acute patients, consisting of subjects
who were diagnosed with PAD or experienced an ischaemic
stroke from at least 1 week up to 6 months before enrolment
or MI within up to 35 days before enrolment. Detailed study
inclusion criteria are shown in Table S3.
Although all the studies enrolled patients with chronic
CAD or PAD, only 3 of them reported the proportion of
patients with either disease. The percentage of patients with
chronic CAD ranged from 47.7% [1] to 90.8% [15]. The pro-
portion of patients with PAD ranged from 21.9% [20] to
27.4% [15].
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All of the included studies reported data on the percent-
age of patients with stroke/cerebrovascular disease, which
ranged from 3.7% [15] to 35.6% [1].
Outcome definitions in included studies varied. It was par-
ticularly evident for major bleeding. In the COMPASS trial
[15], the definition of major bleeding was based on the modi-
fied International Society on Thrombosis and Haemostasis
(ISTH) criteria, while the remaining studies defined the event
according to the ISTH [20], Thrombolysis in Myocardial
Infarction (TIMI) classification [20], the Global Utilization
of Streptokinase and Tpa for Occluded Arteries (GUSTO)
[1] criteria, or other adopted trial-specific criteria [19].
All included studies were double-blinded trials, and all of
them reported detailed information on sequence generation
method and allocation concealment. Intention to treat popu-
lation was a primary analysis set in all eligible studies—risk of
Table 1: Inclusion and exclusion criteria.
Domain Inclusion criteria Exclusion criteria
Population Population of both chronic CAD or PAD patients
Children and adolescents (<18 years old)
Studies evaluated only patients with CAD
Studies evaluated only patients with PAD
Interventions
(i) Xaban/direct thrombin inhibitors (rivaroxaban, dabigatran,
apixaban, edoxaban, betrixaban)
(ii) Antiplatelet (ASA, clopidogrel, ticagrelor,
ticlopidine, triflusal, and prasugrel)
(iii) Dipyridamole
(iv) Cilostazol
(v) Vorapaxar
(vi) Parenteral anticoagulants (low molecular weight
heparin, unfractionated heparin, fondaparinux)
(vii) Vitamin K antagonists (not limited to warfarin)
Comparators Interventions + placebo
Outcomes of interest
Efficacy including:
(i) Composite outcomes:
(a) Stroke/MI/CV death
(b) CHD death/MI/IS/ALI
(c) CV death/MI/IS/ALI
(ii) Individual components of composite outcomes
(iii) All-cause mortality
(iv) Amputations
(v) HF
(vi) Unstable angina
(vii) Revascularisation
(viii) Bypass graft failure (occlusion)
(ix) Stent thrombosis
(x) MALE
(xi) Venous thromboembolism
(xii) Haemorrhagic stroke
(xiii) Chronic limb ischaemia
Safety including:
(i) Major or severe bleeding
(ii) Fatal bleeding
(iii) Intracranial bleeding
(iv) Bleeding requiring re-operation
(v) Bleeding requiring hospitalisation
(vi) Total serious AEs
(vii) Total severe AEs
(viii) Gastrointestinal bleeding
(ix) Discontinuations (any, due to AEs)
Study design
Study type:
(i) RCTs
(ii) Extensions of RCTs
Study type:
(i) Review
(ii) Opinion, editorial, letter
Publication type Full-text papers, conference abstracts > 2014 Conference abstracts ≤ 2014
AEs: adverse events; ALI: acute limb ischaemia; CAD: coronary artery disease; CV: cardiovascular; HF: heart failure; IS: ischaemic stroke; MALE: major adverse
limb events; MI: myocardial infarction; PAD: peripheral artery disease; RCT: randomised controlled trial; ASA: acetylsalicylic acid.
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bias due to missing outcome data was low. There was no evi-
dence to suggest the selective outcomes reporting in all
included studies. The assessment of risk of bias of all included
studies is presented in Table S4.
4.2. Study Results. The present SR focused on the outcomes of
clinical relevance—composites of major adverse cardiovascu-
lar events, all-cause mortality, CV death, ischaemic stroke,
major adverse limb events (MALE), and major bleedings in
the light of the antiplatelet and anticoagulant medication
strategies. The results are presented in Table 3 and on
Figure 2. Additional results are presented in Table S5. The
full list of included studies with corresponding publications
is presented in Table S6.
4.2.1. Clopidogrel Alone. The efficacy and safety of clopido-
grel alone compared to ASA alone were reported in the
CAPRIE study [19]. At a median time of follow-up of 22.9
months, no significant difference in ischaemic stroke, all-
cause mortality, and CV death was observed between clopi-
dogrel alone and ASA alone. The risk of major bleeding
was comparable between clopidogrel alone and ASA alone.
4.2.2. Clopidogrel Plus ASA. The efficacy and safety of clopi-
dogrel plus ASA compared to ASA alone were investigated
in the CHARISMA [1] study. At a median follow-up of 28
months, no difference between clopidogrel plus ASA and
ASA alone was identified in the composite of CV death,
MI, and stroke, as well as all-cause mortality, and CV death.
The risk of major bleeding was comparable between clopido-
grel plus ASA and ASA alone.
4.2.3. Rivaroxaban Plus ASA. The efficacy and safety of rivar-
oxaban plus ASA compared to ASA alone was investigated in
the COMPASS study [15], with a mean follow-up of 23
months. The risk of the composite of CV death, MI, and
stroke was significantly lower for rivaroxaban plus ASA in
comparison to ASA alone. The secondary composite out-
comes (coronary heart disease death, MI, ischaemic stroke,
acute limb ischaemia, and CV death, MI, ischaemic stroke,
acute limb ischaemia) occurred in fewer patients in the rivar-
oxaban plus ASA group compared to the ASA alone group.
Rivaroxaban plus ASA was associated with a nonsignificant
difference in all-cause mortality. Rivaroxaban plus ASA com-
pared to ASA alone significantly reduced the risk of CV death
and ischaemic stroke. Compared to ASA alone, rivaroxaban
plus ASA significantly lowered the incidence of MALEs.
Major bleeding with rivaroxaban 2.5mg bid plus ASA was
significantly increased compared to ASA alone.
4.2.4. Rivaroxaban Alone. The efficacy and safety of rivarox-
aban alone compared to ASA alone were investigated in the
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Table 3: Key efficacy and safety results.
Outcome Study
Follow-up
(months)
Interventions N
N with
event
% with
event
Comparison
HR (LCI; UCI)
N/100
p-yrs
CV death/MI/stroke
CHARISMA,
NCT00050817 [1]
Median: 28
Clopidogrel 75mg od
+ASA 75-162mg od
7802 534 6.80 0.93 (0.83; 1.05) 2.93‡
ASA 75-162mg od 7801 573 7.30 Ref. 3.15‡
COMPASS,
NCT01776424 [15]
Mean: 23
Rivaroxaban 5mg bid 9117 448 4.90 0.90 (0.79; 1.03) 2.60^
Rivaroxaban 2.5mg bid
+ASA 100mg od
9152 379 4.10 0.76 (0.66; 0.86) 2.18^
ASA 100mg od 9126 496 5.40 Ref. 2.88^
TRA 2°P–TIMI 50,
NCT00526474 [20]
Median: 30
Vorapaxar 2.5mg od 13225 1028 9.30† 0.87 (0.80; 0.94) 3.11‡
Placebo 13224 1176 10.50† Ref. 3.56‡
CHD
death/MI/IS/ALI
COMPASS,
NCT01776424 [15]
Mean: 23
Rivaroxaban 5mg bid 9117 397 4.40 0.88 (0.77; 1.01) 2.31^
Rivaroxaban 2.5mg bid
+ASA 100mg od
9152 329 3.60 0.72 (0.63; 0.83) 1.89^
ASA 100mg od 9126 450 4.90 Ref. 2.62^
CV
death/MI/IS/ALI
COMPASS,
NCT01776424 [15]
Mean: 23
Rivaroxaban 5mg bid 9117 453 5.00 0.88 (0.77; 0.99) 2.63^
Rivaroxaban 2.5mg bid
+ASA 100mg od
9152 389 4.30 0.74 (0.65; 0.85) 2.24^
ASA 100mg od 9126 516 5.70 Ref. 3.00^
All-cause mortality
CAPRIE [19] Mean: 22.9
Clopidogrel 75mg od 9599 560 3.00†
0.98 (0.87;
1.10)‡
3.18‡
ASA 325mg od 9586 571 3.10† Ref. 3.26‡
CHARISMA,
NCT00050817 [1]
Median: 28
Clopidogrel 75mg od
+ASA 75-162mg od
7802 371 4.80 0.99 (0.83; 1.14) 2.04‡
ASA 75-162mg od 7801 374 4.80 Ref. 2.05‡
COMPASS,
NCT01776424 [15]
Mean: 23
Rivaroxaban 5mg bid 9117 366 4.00 0.97 (0.84; 1.12) 2.09^
Rivaroxaban 2.5mg bid
+ASA 100mg od
9152 313 3.40 0.82 (0.71; 0.96) 1.78^
ASA 100mg od 9126 378 4.10 Ref. 2.16^
TRA 2°P–TIMI 50,
NCT00526474 [20]
Median: 30
Vorapaxar 2.5mg od 13225 540 5.00† 0.95 (0.85; 1.07) 1.63‡
Placebo 13224 565 5.30† Ref. 1.71‡
CV death
CAPRIE [19] Mean: 22.9
Clopidogrel 75mg od 9599 350 1.90†
0.92 (0.80;
1.07)‡
1.98‡
ASA 325mg od 9586 378 2.06† Ref. 2.16‡
CHARISMA,
NCT00050817 [1]
Median: 28
Clopidogrel 75mg od
+ASA 75-162mg od
7802 238 3.10 1.04 (0.87; 1.25) 1.31‡
ASA 75-162mg od 7801 229 2.90 Ref. 1.26‡
COMPASS,
NCT0177642 [15]
Mean: 23
Rivaroxaban 5mg bid 9117 195 2.10 0.96 (0.79; 1.17) 1.11^
Rivaroxaban 2.5mg bid
+ASA 100mg od
9152 160 1.70 0.78 (0.64; 0.96) 0.91^
ASA 100mg od 9126 203 2.20 Ref. 1.16^
TRA 2°P–TIMI 50,
NCT00526474 [20]
Median: 30
Vorapaxar 2.5mg od 13225 285 2.70† 0.89 (0.76; 1.04) 0.86‡
Placebo 13224 319 3.00† Ref. 0.96‡
6 Cardiovascular Therapeutics
COMPASS study [15], with a mean time of follow-up of 23
months. No significant difference was identified in terms of
the incidence of the composite of CV death, MI, and stroke,
and the composite of coronary heart disease death, MI, and
ischaemic stroke, and the risk of all-cause mortality for rivar-
oxaban alone compared to ASA alone. Rivaroxaban alone
significantly reduced the incidence of the composite of CV
death, MI, and ischaemic stroke, and acute limb ischaemia,
the incidence of MALEs in comparison to ASA alone as well
as the incidence of ischaemic stroke. The rate of major bleed-
ings was significantly higher in the rivaroxaban group than in
the ASA group.
4.2.5. Vorapaxar. The efficacy and safety of vorapaxar was
compared to placebo in the TRA 2°P–TIMI 50 [20] study
with a median follow up of 30 months. Compared to placebo,
vorapaxar significantly reduced the incidence of composite
MI, stroke, and CV death, with no significant reduction in
ischaemic stroke, all-cause mortality, as well as CV death.
Vorapaxar showed a higher incidence of major bleeding
when compared to placebo.
5. Discussion
Recently, several SRs were published that focused on pure
CAD [21–24] or pure PAD [25, 26] populations.
In an SR investigating different antiplatelet agents for the
prevention of major cardiovascular events and leg amputa-
tions in patients with PAD showed that clopidogrel should
be the indicated antiplatelet agent in this group of patients
[26]. Another study showed that dual antiplatelet therapy
(DAPT) is beneficial for preventing thrombosis after revas-
cularisation in PAD comparing to ASA monotherapy [25].
DAPT is also recommended after drug-eluting stent
Table 3: Continued.
Outcome Study
Follow-up
(months)
Interventions N
N with
event
% with
event
Comparison
HR (LCI; UCI)
N/100
p-yrs
IS
CAPRIE [19] Mean: 22.9
Clopidogrel 75mg od 9553 315‡ 3.30‡
0.95 (0.83;
1.08)‡
1.79‡
ASA 325mg od 9546 338‡ 3.50‡ Ref. 1.93‡
COMPASS,
NCT01776424 [15]^ Mean: 23
Rivaroxaban 5mg BID 9117 83 0.90 0.66 (0.50; 0.88) 0.48^
Rivaroxaban 2.5mg
BID+ASA 100mg od
9152 64 0.70 0.51 (0.38; 0.69) 0.36^
ASA 100mg od 9126 125 1.40 Ref. 0.72^
TRA 2°P–TIMI 50,
NCT00526474 [20]
Median: 30
Vorapaxar 2.5mg od 13225 250 2.20† 0.85 (0.72; 1.01) 1.23‡
Placebo 13224 294 2.60† Ref. 1.79‡
Major Adverse Limb
Event (MALE)
COMPASS,
NCT01776424 [15]
Mean: 23
Rivaroxaban 5mg bid 9117 41 0.40 0.64 (0.43; 0.95) 0.23^
Rivaroxaban 2.5mg bid
+ASA 100mg od
9152 34 0.40 0.53 (0.35; 0.80) 0.19^
ASA 100mg od 9126 64 0.70 Ref. 0.37^
Major bleedings
CAPRIE∗ [19] Mean: 22.9
Clopidogrel 75mg od 9599 132 1.38
0.88
(0.70;1.12)‡
0.75‡
ASA 325mg od 9586 149 1.55 Ref. 0.85‡
CHARISMA,
NCT00050817∗∗ [1]
Median: 28
Clopidogrel 75mg od
+ASA 75-162mg od
7802 130 1.70 1.25 (0.97; 1.61) 0.71‡
ASA 75-162mg od 7801 104 1.30 Ref. 0.57‡
COMPASS,
NCT01776424∗∗∗ [15]
Mean: 23
Rivaroxaban 5mg bid 9117 255 2.8 1.51 (1.25; 1.84) 1.48^
Rivaroxaban 2.5mg bid
+ASA 100mg od
9152 288 3.1 1.70 (1.40; 2.05) 1.67^
ASA 100mg od 9126 170 1.9 Ref. 0.98^
TRA 2°P–TIMI 50,
NCT00526474∗∗ [20]
Median: 30
Vorapaxar 2.5mg od 13186 438 4.20† 1.66 (1.43; 1.93) 1.33‡
Placebo 13166 267 2.50† Ref. 0.81‡
TRA 2°P–TIMI 50,
NCT00526474∗∗∗∗ [20]
Vorapaxar 2.5mg od 13186 298 2.90† 1.44 (1.21; 1.72) 0.90‡
Placebo 13166 209 1.90† Ref. 0.63‡
TRA 2°P–TIMI 50,
NCT00526474∗∗∗∗∗ [20]
Vorapaxar 2.5mg od 13186 624 5.90† 1.57 (1.38; 1.78) 1.89‡
Placebo 13166 404 3.70† Ref. 1.23‡
∗Trial-specific criteria definition, ∗∗GUSTO severe definition, ∗∗∗Modified ISTH definition, ∗∗∗∗TIMImajor bleeding, ∗∗∗∗∗ISTH definition, ‡Calculated on the
basis of available data, ^Unpublished data extracted from CSR, †Kaplan-Meier estimate. ALI: acute limb ischaemia; ASA: acetylsalicylic acid; bid: bis in die =
twice a day; CHD: coronary heart disease; CV: cardiovascular; GUSTO: Global Utilization of Streptokinase and Tpa for Occluded Arteries definition; HR:
hazard ratio; IS: ischaemic stroke; ISTH: International Society on Thrombosis and Haemostasis classification; LCI: lower confidence interval; MI:
myocardial infarction; od: once a day; p-yrs: Patients-years; Ref.: reference group; UCI: upper confidence interval.
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implantation; however, the optimum duration remains
uncertain [23]. In a group of patients treated beyond 1 year,
myocardial infarction and stent thrombosis were reduced;
however, it was associated with increased mortality [23].
Another study showed that treatment of patients with acute
coronary disease or prior myocardial infarction with DAPT
(ASA plus ticagrelor) or triple therapy (ASA, clopidogrel,
and very low dose rivaroxaban) was associated with lower
cardiovascular mortality, but with increasing risk of major
bleeding [22]. In an SR comparing ASA treatment with clopi-
dogrel monotherapy in the treatment of stable CAD patients,
no difference was found [24]. Furthermore the administra-
tion of prasugrel and ticagrelor led to a significant reduction
in the incidence of major ischaemic events in the patients
with CAD comparing to clopidogrel [21].
Although none of these SRs evaluated a broad effect on
the population consist of both CAD and PAD patients. Tak-
ing this into consideration, this SR summarises the efficacy
0.5 1.0 2.0
Hazard ratio versus reference treatment 
RIV 2.5 mg bid+ ASA 100 mg
RIV 5 mg bid
CLO75 mg od+ ASA 75-162 mg
CLO75 mg od
Hazard ratios versus reference treatment 
More effective
than reference
Less effective
than reference 
CV death/MI/stroke
CHD death/MI/IS/ALI
CV death/ MI/IS/ALI
All-cause mortality
CV death
Major Adverse Limb 
Event (MALE)
Major bleedings
Hazard ratio
[95% CI]
0.76 [0.66, 0.86]
0.90 [0.79, 1.03]
0.93 [0.83, 1.05]
0.87 [0.80, 0.94]
0.72 [0.63, 0.83]
0.88 [0.77, 1.01]
0.74 [0.65, 0.85]
0.88 [0.77, 0.99]
0.82 [0.71, 0.96]
0.97 [0.84, 1.12]
0.99 [0.83, 1.14]
0.98 [0.87, 1.10]
0.95 [0.85, 1.07]
0.78 [0.64, 0.96]
0.96 [0.79, 1.17]
1.04 [0.87, 1.25]
0.92 [0.80, 1.07]
0.89 [0.76, 1.04]
0.53 [0.35, 0.80]
0.64 [0.43, 0.95]
1.70 [1.40, 2.05]
1.51 [1.25, 1.84]
1.25 [0.97, 1.61]
0.88 [0.70, 1.12]
1.66 [1.43, 1.93]
Error bar indicate the 95%CI of the reported HR
Reference
treatment
ASA 100 mg
ASA 100 mg
ASA 75-162 mg
Placebo
ASA 100 mg
ASA 100 mg
ASA 100 mg
ASA 100 mg
ASA 100 mg
ASA 100 mg
ASA 75-162 mg
ASA 325 mg
Placebo
ASA 100 mg
ASA 100 mg
ASA 75-162 mg
ASA 325 mg
Placebo
ASA 100 mg
ASA 100 mg
ASA 100 mg
ASA 100 mg
ASA 75-162 mg
ASA 325 mg
Placebo
Ischemic stroke 0.51 [0.38, 0.69]
0.66 [0.50, 0.88]
0.95 [0.83, 1.08]
0.85 [0.72, 1.01]
ASA 100 mg
ASA 100 mg
ASA 325 mg
Placebo
VOR2.5 mg od
Figure 2: Forest plot with key efficacy and safety results [1, 15, 19, 20]. ASA: acetylsalicylic acid; CLO: clopidogrel; RIV: rivaroxaban; trt:
treatment; VOR: vorapaxar.
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and safety of antiplatelet and anticoagulant regimens for the
prevention of atherothrombotic events only in the popula-
tion of both chronic CAD or PAD patients.
It was found that clopidogrel alone and clopidogrel with
ASA compared to ASA alone presented similar efficacy in
the prevention of atherothrombotic events with comparable
safety profile. Vorapaxar treatment was associated with a
lower incidence of composite MI, stroke, and CV death, with
no significant reduction in mortality, compared to placebo.
The rate of major bleeding was significantly increased in
the vorapaxar group as compared with the placebo group.
Rivaroxaban 5mg bid did not show better cardiovascular
outcomes than ASA alone and resulted in more major bleed-
ing events. Rivaroxaban 2.5mg bid plus ASA showed better
efficacy when given in combination with ASA than ASA
alone; however, this combined therapy increased the risk of
major bleeding.
The current guidelines recommend ASA alone as the
standard of care for the prevention of atherothrombotic
events in patients with chronic CAD or PAD. In the chronic
phase of the disease, patients should maintain single anti-
platelet therapy with ASA (or clopidogrel in ASA-intolerant
patients) to minimise the risk of atherothrombotic events as
well as the risk of bleeding [3–6, 27, 28]. Among identified
studies on the prevention of atherothrombotic events, the
COMPASS [15] study on rivaroxaban was the largest
(n = 27,395) study identified. The study was prematurely ter-
minated due to the superiority of the rivaroxaban plus ASA
group after a mean follow-up of 23 months.
As shown in the COMPASS study [15], patients with
chronic CAD or PAD given a combination of rivaroxaban
and ASA had significantly better prognosis when compared
to patients receiving ASA alone. The rate of the primary out-
come (a composite of CV death, MI and stroke) was lower by
24% with rivaroxaban plus ASA than with ASA alone (4.1%
vs. 5.4%; P < 0:001), but the rate of major bleeding was higher
(3.1% vs. 1.9%; P < 0:001). Earlier, two regimens of clopido-
grel for secondary CV prevention in chronic CAD or PAD
had been investigated: clopidogrel alone [19] and clopidogrel
plus ASA [1].
In 1996, the CAPRIE study [19] including nearly 20,000
patients with either ischaemic stroke, MI, or symptomatic
PAD did not demonstrate superiority of clopidogrel alone
over ASA regarding either all-cause mortality or vascular-
related mortality.
The third-largest study, CHARISMA [1], included nearly
16,000 patients with either documented CAD or symptom-
atic PAD, failed to demonstrate the superiority of dual anti-
platelet therapy (DAPT) strategy based on clopidogrel plus
ASA over ASA alone in terms of the composite of CV death,
MI and stroke, all-cause mortality, and CV death [1]. The
rate of severe bleeding did not differ significantly between
these groups, although a strong trend towards an increased
risk was observed in patients receiving clopidogrel plus ASA.
Rivaroxaban plus ASA compared to ASA alone signifi-
cantly reduced the risk of ischaemic stroke (0.9% vs.
1.4%; P = 0:0035). Similar results were observed for the reg-
iment of rivaroxaban alone versus ASA alone (0.7% vs. 1.4%,
P = 0:00001) [15]. These results may suggest that for a popu-
lation such as the COMPASS population including around
60% of prior MI patients, the prevention of ischaemic stroke
in this population may be relevant.
Evidence identified for chronic CAD or PAD population
is limited. We identified only 4 eligible studies; however,
more than 15,000 hits were screened. No RCT on DAPT with
ticagrelor was identified for the population of interest.
Recently published studies that evaluated ticagrelor, EUCLID
[29] and PEGASUS-TIMI 54 [30], were not included because
they included only patients with symptomatic PAD and with
prior myocardial infarction, respectively.
Only one study has an unclear risk of bias for the rando-
misation method and allocation concealment. Trials with
unclear or inadequate concealment have been shown to report
more favourable effects of experimental treatment [31].
Efficacy and safety of antiplatelets and anticoagulants in
chronic CAD or PAD was investigated in heterogeneous
patient population. The COMPASS [15] study included
patients with chronic atherosclerotic vascular disease, while
the CAPRIE [19] trial recruited a population including both
chronic and acute patients, consisting of subjects who were
diagnosed with PAD or experienced ischaemic stroke from
at least 1 week up to 6 months before enrolment or MI within
up to 35 days before enrolment.
The COMPASS study [15] used the definition of major
bleeding according to modified ISTH criteria that were the
broadest and also comprised of cases presented to an acute
care facility without an overnight stay. Thus, comparison
across studies should be interpreted with caution.
Follow-up duration in included studies varied from 22.9
[32] to 30 months [20]. The outcomes of short-term studies
usually have several limitations resulting from inadequate
power to demonstrate clinically relevant endpoints, lack of
prespecified statistical hypotheses, and potential sensitivity
to changes of hazards during follow-up.
6. Conclusion
This systematic review of efficacy and safety of interven-
tions to prevent atherothrombotic events in patients with
chronic CAD or PAD highlighted the limited evidence
available and revealed population heterogeneity between
trials. Clopidogrel alone and clopidogrel plus ASA did not
demonstrate superiority over ASA alone. The addition of riv-
aroxaban to ASA may increase the risk of bleeding. Rivarox-
aban and ASA may offer patients significant additional
benefits compared to ASA alone.
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